303 related articles for article (PubMed ID: 33259244)
1. Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer.
Brems-Eskildsen AS; Linnet S; Danø H; Luczak A; Vestlev PM; Jakobsen EH; Neimann J; Jensen CB; Dongsgaard T; Langkjer ST
Acta Oncol; 2021 Feb; 60(2):157-164. PubMed ID: 33259244
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer.
Chai Y; Liu J; Jiang M; He M; Wang Z; Ma F; Wang J; Yuan P; Luo Y; Xu B; Li Q
Thorac Cancer; 2023 Aug; 14(23):2259-2268. PubMed ID: 37402471
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
Wang Z; Liu J; Ma F; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Li Q; Xu B
Breast Cancer Res Treat; 2021 Jul; 188(2):441-447. PubMed ID: 33895900
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.
Munzone E; Regan MM; Cinieri S; Montagna E; Orlando L; Shi R; Campadelli E; Gianni L; Palleschi M; Petrelli F; Bengala C; Generali D; Collovà E; Puglisi F; Cretella E; Zamagni C; Chini C; Ruepp B; Loi S; Colleoni M;
JAMA Oncol; 2023 Sep; 9(9):1267-1272. PubMed ID: 37440239
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
[TBL] [Abstract][Full Text] [Related]
6. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
[TBL] [Abstract][Full Text] [Related]
7. Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Freyer G; Martinez-Jañez N; Kukielka-Budny B; Ulanska M; Bourgeois H; Muñoz M; Morales S; Calero JB; Cortesi L; Pintér T; Palácová M; Cherciu N; Petru E; Ettl J; de Almeida C; Villanova G; Raymond R; Minh CTT; Rodrigues A; Cazzaniga ME
Breast; 2024 Apr; 74():103681. PubMed ID: 38377732
[TBL] [Abstract][Full Text] [Related]
8. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
Cazzaniga ME; Cortesi L; Ferzi A; Scaltriti L; Cicchiello F; Ciccarese M; Della Torre S; Villa F; Giordano M; Verusio C; Nicolini M; Gambaro AR; Zanlorenzi L; Biraghi E; Legramandi L; Rulli E;
Breast Cancer Res Treat; 2016 Dec; 160(3):501-509. PubMed ID: 27752847
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046.
Krajnak S; Decker T; Schollenberger L; Rosé C; Ruckes C; Fehm T; Thomssen C; Harbeck N; Schmidt M
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3391-3400. PubMed ID: 33743073
[TBL] [Abstract][Full Text] [Related]
11. CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients.
Bailleux C; Arnaud A; Frenel JS; Chabaud S; Bachelot T; You B; Stefani L; Tixidre CG; Simon H; Beal-Ardisson D; Jacquin JP; Del Piano F; Lortholary A; Cornea C; Greilsamer C; Largillier R; Brocard F; Legouffe E; Atlassi M; Hardy-Bessard AC; Heudel PE
Breast Cancer; 2023 Mar; 30(2):315-328. PubMed ID: 36602669
[TBL] [Abstract][Full Text] [Related]
12. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines.
Campone M; Dobrovolskaya N; Tjulandin S; Chen SC; Fourie S; Mefti F; Konstantinova M; Lefresne F; Meheust N; Jassem J
Breast J; 2013; 19(3):240-9. PubMed ID: 23528159
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
Welt A; von Minckwitz G; Oberhoff C; Borquez D; Schleucher R; Loibl S; Harstrick A; Kaufmann M; Seeber S; Vanhoefer U
Ann Oncol; 2005 Jan; 16(1):64-9. PubMed ID: 15598940
[TBL] [Abstract][Full Text] [Related]
14. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
[TBL] [Abstract][Full Text] [Related]
16. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial.
He M; Liu J; Wang Z; Ma F; Wang J; Zhang P; Li Q; Yuan P; Luo Y; Fan Y; Mo H; Lan B; Li Q; Xu B
Breast; 2023 Dec; 72():103581. PubMed ID: 37742492
[TBL] [Abstract][Full Text] [Related]
18. Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.
Strada MR; Palumbo R; Bernardo A; Riccardi A; Teragni C; Poggi G; Frascaroli M; Amatu A; Montagna B; Sottotetti F; Tagliaferri B; Bernardo G
Clin Breast Cancer; 2012 Feb; 12(1):30-9. PubMed ID: 22154360
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
Montagna E; Palazzo A; Maisonneuve P; Cancello G; Iorfida M; Sciandivasci A; Esposito A; Cardillo A; Mazza M; Munzone E; Lai A; Goldhirsch A; Colleoni M
Cancer Lett; 2017 Aug; 400():276-281. PubMed ID: 28131905
[TBL] [Abstract][Full Text] [Related]
20. Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies.
Petrelli F; Di Cosimo S; Lonati V; Barni S
Clin Breast Cancer; 2016 Oct; 16(5):327-334. PubMed ID: 27282844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
